Coughlin Timothy 4
4 · Travere Therapeutics, Inc. · Filed May 19, 2026
Research Summary
AI-generated summary of this filing
Travere (TVTX) Director Timothy Coughlin Sells 3,250 Shares
What Happened Timothy Coughlin, a director of Travere Therapeutics (TVTX), reported a sale of 3,250 shares on 2026-05-15. The shares were sold at $43.49 per share for a total transaction value of approximately $141,343. This was a sale (not a purchase) and is often considered a routine disposition rather than a bullish signal.
Key Details
- Transaction date: 2026-05-15
- Price: $43.49 per share
- Shares sold: 3,250
- Total value: ~$141,343
- Filing date (Form 4): 2026-05-19 (reporting the 2026-05-15 transaction)
- Shares owned after transaction: not provided in the excerpt of this filing
- Footnote: Sale was made pursuant to a written Rule 10b5-1(c) trading plan adopted on November 19, 2025
Context A 10b5-1 plan indicates the sale was prearranged under a written plan that can provide an affirmative defense against insider trading claims; it does not necessarily reflect the insider’s current view of the company. No other derivative, gift, or option-exercise activity is reported in this filing. Check the full SEC Form 4 for complete ownership figures and any additional filings for related transactions.
Insider Transaction Report
- Sale
Common Stock
[F1]2026-05-15$43.49/sh−3,250$141,343→ 52,250 total
Footnotes (1)
- [F1]This sale was made pursuant to a written plan adopted on November 19, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.